Article
Medicine, General & Internal
Laida Elberdin, Rosa M. Fernandez-Torres, Maria Mateos, Maria Outeda, Eva Blanco, Maria I. Gomez-Besteiro, Isabel Martin-Herranz, Eduardo Fonseca
Summary: This study found a positive correlation between ustekinumab concentration and clinical response in psoriatic patients, suggesting ustekinumab concentration could be used to predict treatment efficacy. The presence of anti-ustekinumab antibodies may serve as a potential cause for treatment failure.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Kangzhi Chen, Fei Jiang, Qian Zhou, Xiaohua Dong, Ting He, Yi Li, Zhaohui Luo, Weiwei Duan, Huan Yang
Summary: The study found a high prevalence of latent tuberculosis infection (LTBI) among myasthenia gravis (MG) patients, especially among older age groups and males. However, receiving immunosuppressive therapies does not seem to increase the risk of LTBI reactivation. Screening for LTBI is strongly recommended for all MG patients ready to receive treatment, and preventive anti-tuberculosis chemotherapy should be prescribed after considering the potential benefits and risks in LTBI patients.
ANNALS OF MEDICINE
(2023)
Article
Dermatology
Ricardo Ruiz-Villaverde, Fiorella Vasquez Chinchay, Lourdes Rodriguez-Fernandez-Freire, Jose C. Armario-Hita, Amalia Perez-Gil, Manuel Galan-Gutierrez
Summary: This retrospective observational study examined the outcomes of psoriatic patients with moderate-to-severe psoriasis who switched from ustekinumab to guselkumab treatment. The results showed that guselkumab administered every 12 weeks without induction achieved good effectiveness and safety profiles in clinical practice.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Matteo Megna, Maria Ferrillo, Angelo Ruggiero, Eleonora Cinelli, Lucia Gallo, Gabriella Fabbrocini
Summary: Overall, the study found that 6.5% of psoriasis patients undergoing biologic treatment experienced QFT conversion over an average treatment duration of 3.2 years, with conversion typically occurring after around 34.05 months of treatment. Anti-TNF-alpha drugs, particularly adalimumab, were most commonly associated with QFT conversion, followed by anti-IL-12/23 and anti-IL-17 therapies.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Wai Sze Agnes Chan, Yisheng Wong, Hazel Hwee Boon Oon, Colin Thiam Seng Theng, Wei-Sheng Chong
Summary: This study assessed the efficacy and safety of ustekinumab in treating patients with moderate to severe plaque psoriasis. The results showed that ustekinumab effectively improved the condition in patients with recorded improvements in psoriasis area and severity index (PASI) and body surface area (BSA). In terms of safety, no serious adverse events were reported. In conclusion, ustekinumab is a safe and efficacious treatment for patients with moderate to severe plaque psoriasis in a multiethnic Asian population.
SINGAPORE MEDICAL JOURNAL
(2023)
Article
Immunology
Hung-Ling Huang, Wei-Chang Huang, Kun-Der Lin, Shin-Shin Liu, Meng-Rui Lee, Meng-Hsuan Cheng, Chun-Shih Chin, Po-Liang Lu, Chau-Chyun Sheu, Jann-Yuan Wang, I-Te Lee, Inn-Wen Chong
Summary: The study found that the prevalence of latent tuberculosis infection was over 25% in elderly patients with poorly controlled diabetes mellitus under the care of a collaborative multidisciplinary team. Despite a high completion rate of preventive therapy, some patients still experienced adverse drug reactions.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Seung-Won Jung, Sung Ha Lim, Jae Joon Jeon, Yeon-Woo Heo, Mi Soo Choi, Seung-Phil Hong
Summary: This study compared the efficacy, safety, and drug survival of three commonly used psoriasis biologics and identified factors affecting drug survival. Guselkumab showed superior long-term response and complete remission compared to other biologics, while ustekinumab had lower efficacy. All three biologics had similar safety profiles, but had different side effects.
Article
Dermatology
Georgios Kokolakis, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda Gooderham, Andreas Koerber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Summary: This study evaluated the efficacy and safety of switching to bimekizumab from adalimumab, ustekinumab, and secukinumab. The results showed rapid and durable improvements in clinical responses among nonresponders who switched to bimekizumab. Furthermore, the majority of patients who responded well to previous treatments maintained or improved their response after switching to bimekizumab. Overall, switching to bimekizumab was found to be highly effective and well tolerated for psoriasis patients.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Wang, Christopher Cioffi, Veerle Vanvoorden, Mark Lebwohl
Summary: Bimekizumab was more effective than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis, with a safety profile consistent with previous studies.
Article
Immunology
Alexander L. Chu, Leonid W. Lecca, Roger Calderon, Carmen C. Contreras, Rosa M. Yataco, Zibiao Zhang, Mercedes C. Becerra, Megan B. Murray, Chuan-Chin Huang
Summary: This study found that the adverse effects of smoking on the transmissibility of tuberculosis are significantly reduced shortly after quitting smoking, emphasizing the importance of smoking cessation interventions in tuberculosis control.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Dermatology
Yue Xiao, Wenyao Mi, Jinqiu Wang, Dingke Wen, Yiyi Wang, Yuanxia Gu, Dan Hao, Wei Li, Xuerong Chen, Wei Li
Summary: This study provides additional information on the safety of secukinumab in patients with psoriasis and latent tuberculosis infection. The results showed no significant increase in IGRA results in both groups, regardless of whether patients received prophylactic treatment. Further research is needed to determine the necessity of anti-TB medication before administering secukinumab.
DERMATOLOGY AND THERAPY
(2023)
Article
Dermatology
Yue Xiao, Wenyao Mi, Jinqiu Wang, Dingke Wen, Yiyi Wang, Yuanxia Gu, Dan Hao, Wei Yan, Xuerong Chen, Wei Li
Summary: This study investigated the safety of using secukinumab in patients with psoriasis with latent tuberculosis infection (LTBI). The results showed no activation of tuberculosis in either group, regardless of whether patients received antituberculosis therapy. The interferon-gamma release assay also did not show a significant increase after balancing the baseline. Therefore, this study indicates that secukinumab is safe in patients with LTBI, even without antituberculosis treatment.
DERMATOLOGY AND THERAPY
(2023)
Article
Pharmacology & Pharmacy
Wangda Zhou, Chuanpu Hu, Yaowei Zhu, Bruce Randazzo, Michael Song, Amarnath Sharma, Zhenhua Xu, Honghui Zhou
Summary: A population pharmacokinetic model and a joint longitudinal exposure-response model were developed to characterize the PK and exposure-response relationship of ustekinumab in pediatric patients with psoriasis. The models predicted the PK of ustekinumab and the clinical response in pediatric patients with psoriasis, showing efficacy and safety in this population.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune, Matteo Megna
Summary: Biological treatments have revolutionized the management of moderate-to-severe psoriasis, and bimekizumab, a novel IL-17 inhibitor, shows unique efficacy and safety profiles compared to other biologics. This review evaluates the safety of bimekizumab in treating moderate-to-severe plaque psoriasis and highlights its superior efficacy compared to other biological classes.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Immunology
Nicole C. Ammerman, Eric L. Nuermberger, Andrew Owen, Steve P. Rannard, Caren Freel Meyers, Susan Swindells
Summary: This article provides an overview of the specific considerations and current preclinical advancements related to the development of long-acting technologies for tuberculosis drugs to treat latent infection, including target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Dermatology
April Armstrong, Luis Puig, Richard Langley, Tsen Fang Tsai, Michael Song, Yasmine Wasfi, Jingzhi Jiang, Shu Li, Chenglong Han
JOURNAL OF DERMATOLOGICAL TREATMENT
(2019)
Article
Allergy
Tom C. Chan, Riana D. Sanyal, Ana B. Pavel, Jacob Glickman, Xiuzhong Zheng, Hui Xu, Yung-Tsu Cho, Tsen-Feng Tsai, Huei-Chi Wen, Xiangyu Peng, Inna Cueto, James G. Krueger, Emma Guttman-Yassky
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2018)
Article
Engineering, Biomedical
Sabrina Mai-Yi Fan, Po-Hua Chen, Yu-Ting Tseng, Jin-Bon Hong, Wannhsin Chen, Tsen-Fang Tsai, Sung-Jan Lin
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
(2018)
Article
Dermatology
Tsen-Fang Tsai, Gwang Seong Choi, Beom Joon Kim, Moon-Bum Kim, Chi Fai Ng, Puja Kochhar, Stacy Jasper, Betsy Brotherton, Barbara Orban, Zrinka Lulic
JOURNAL OF DERMATOLOGY
(2018)
Article
Rheumatology
Mark C. Genovese, Benard Combe, Joel M. Kremer, Tsen-Fang Tsai, Frank Behrens, David H. Adams, Chin Lee, Lisa Kerr, Peter Nash
Article
Multidisciplinary Sciences
Chi-Zai Sin, Ting-Shun Wang, Hsien-Yi Chiu, Tsen-Fang Tsai
Letter
Medicine, General & Internal
Herve Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, A. David Burden, Tsen-Fang Tsai, Akimichi Morita, Hamida Turki, David B. Hall, Michael Shear, Patrick Baum, Steven J. Padula, Christian Thoma
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Review
Immunology
Ting-Shun Wang, Tsen-Fang Tsai
Review
Dermatology
Ya-Chu Tsai, Tsen-Fang Tsai
DERMATOLOGY AND THERAPY
(2019)
Review
Biochemistry & Molecular Biology
Ya-Chu Tsai, Tsen-Fang Tsai
Summary: Psoriasis and atopic dermatitis are now considered to be a spectrum of disease, with overlapping genetic loci and immunopathogenesis. The clinical presentations also have similarities.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Chemistry, Medicinal
Hao-Jui Weng, Quoc Thao Trang Pham, Chia-Wei Chang, Tsen-Fang Tsai
Summary: Pain and itch are important manifestations of various disorders and share mediators and neural circuitry. Concurrent treatment for pain and itch is significant.
Article
Pharmacology & Pharmacy
Jin-Bon Hong, Po-Yuan Wu, Albert Qin, Yi-Wen Huang, Kuan-Chiao Tseng, Ching-Yu Lai, Wing-Kai Chan, Jane Fang, David L. Cutler, Tsen-Fang Tsai
Summary: This study investigates the safety and activity of KX01 ointment in patients with plaque-type psoriasis and shows that KX01 1% has promising activity for the treatment of this condition.
Review
Pharmacology & Pharmacy
Ya-Chu Tsai, Chen-Yiu Hung, Tsen-Fang Tsai
Summary: Recommendations on selecting biologics and targeted synthetic small molecules for refractory HS can be made by comparing the efficacy and safety of these medications. Adalimumab, bimekizumab, secukinumab 300 mg q4w, and secukinumab 300 mg q2w showed superior outcomes compared to placebo in terms of HiSCR at 12-16 weeks. There were no significant differences between bimekizumab and adalimumab in terms of HiSCR and DLQI 0/1.
Article
Biochemistry & Molecular Biology
I-Heng Chiu, Tsen-Fang Tsai
Summary: Ixekizumab (Taltz(®)) is a humanized anti-IL-17A monoclonal antibody used to treat inflammatory diseases. Overweight or obesity may be protective against ixekizumab-induced injection site reactions, while a positive family history of psoriasis may be a potential risk factor. Additionally, patients experiencing diarrhea after ixekizumab injection are at higher risk for developing injection site reactions.
Article
Pharmacology & Pharmacy
Kai-Lung Chen, Hsien-Yi Chiu, Jui-Hsiang Lin, Jian-De Ye, Yi-Hsuan Cho, Ko-Jen Li, Tsen-Fang Tsai
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2019)